Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study

The Lancet HIV 2026 Open access

Read full text
Authors: Aditya H. Gaur, Kristin Baltrusaitis, E. Capparelli, John H Moye, Dwight E Yin, Gaerolwe Masheto, Sarah Buisson, Conn Harrington, Mark A. Marzinke, Elizabeth D. Lowenthal, Rachel Scheckter, Andi Ace
+41 more S. M. Ward, Ryan Milligan, Kyle Whitson, Jenny Huang, S Y Amy Cheung, Brookie M. Best, Ellen Townley, Gilly Roberts, Thomas N. Kakuda, Eileen Birmingham, Sisinyana Ruth Mathiba, Linda Aurpibul, Violet Korutaro, C. Estelle Smith, Faeezah Patel, Evette Moodley, Carolyn Bolton-Moore, Allison L Agwu, Avy Violari, Pradthana Ounchanum, Maxensia Owor, Kulkanya Chokephaibulkit, Andres Camacho-Gonzalez, Mary Paul, Samantha Fry, Jennifer Jao, Charles D Mitchell, Sara Zabih, Rodica M Van Solingen-Ristea, Anna Dari, Herta Crauwels, Veerle Van Eygen, Kati Vandermeulen, Ann M. Buchanan, Yu-Wei Lin, Isabelle Déprez, Kelong Han, Susan L. Ford, Jon Collins, Barbara Heckman, Chelsea Stotz
DOI: 10.1016/s2352-3018(25)00242-5
Cited by: 4
References: 19

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV-related health complications and treatments Virus-based gene therapy research

Publication details

Journal / source
The Lancet HIV
Publisher
Elsevier BV
Volume
13
Issue
2
Pages
e85–e94
Publication date
15 January 2026
Language
EN